Clinical Research Directory
Browse clinical research sites, groups, and studies.
GRACE-DE: Prospective Multicenter Real-world Gastric Cancer Patients Starting AZ-developed and Approved Drugs in Germany (Umbrella Study)
Sponsor: AstraZeneca
Summary
This is a prospective, non-interventional, observational, multicentre study evaluating the real-world effectiveness and safety of AstraZeneca-developed and approved medicines used to treat gastric and/or oesophageal cancers in Germany. The study is designed as an umbrella study comprising several drug- and indication-specific modules. The present description covers Module A, which evaluates durvalumab used perioperatively in combination with FLOT chemotherapy (D-FLOT), followed by adjuvant durvalumab monotherapy in adults with resectable gastric or gastro-oesophageal junction adenocarcinoma in routine clinical practice in Germany.
Official title: Prospective, Observational, Multicenter, and Multicohort Study of Patients With Gastric Cancer Initiating AstraZeneca-developed and Approved Drugs in Germany GastRic CAnCEr Real-World Evidence Germany (Umbrella Study)
Key Details
Gender
All
Age Range
18 Years - 130 Years
Study Type
OBSERVATIONAL
Enrollment
300
Start Date
2026-10-31
Completion Date
2031-09-30
Last Updated
2026-10-20
Healthy Volunteers
No